ClinicalTrials.gg
Active, not recruitingNCT05327959Updated Feb 13, 2026

A.L.P.S. Clavicle Plating System PMCF

An interventional study of Clavicle open reduction and internal fixation in Clavicle Fracture and Clavicle Injury, sponsored by Zimmer Biomet. Active, not recruiting at 5 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by Zimmer Biomet · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
98
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

A commercially available product clinical study which aims to confirm the safety, performance, and clinical benefits to the patient of the ALPS Clavicle Plating system for both the implant itself and the instrumentation used during surgery.

Read the detailed description

The objectives of this observational, prospective study with optional retrospective enrollment are to confirm safety, performance and clinical benefits of the A.L.P.S Clavicle Plating System and its instrumentation by analysis of fracture healing, functional outcome and adverse events.

The safety of the system will be assessed by monitoring the frequency and incidence of adverse events including re-operations. Relation of the events to implant, instrumentation and/or procedure should be specified.

The performance will be evaluated by assessment of fracture/osteotomy healing and functional outcome of all enrolled study subjects.

02

Conditions studied

  • Clavicle Fracture
  • Clavicle Injury

Keywords

  • clavicle
03

In context

Lead sponsor

Zimmer Biomet is the lead sponsor of 275 studies on the registry; 28 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 19 (86%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient must be 18 years of age or older.
  • Patient must have a clavicle fracture requiring surgical intervention and be eligible for fixation by locking plate and screws.
  • Unilateral or Bilateral fractures.
  • Patient must be capable of understanding the doctor's explanation, following doctor's instruction, is able to and willing to complete the protocol required follow-up.
  • Patient must have a signed IRB/EC approved .

Exclusion criteria

Exclusion Criteria:

  • Active infection.
  • Patients presenting conditions including blood supply limitations, insufficient quantity or quality of bone.
  • Patients with mental or neurologic conditions who are unwilling or incapable of giving proper , following postoperative care instructions.
  • Foreign body sensitivity where material sensitivity is suspected, testing is to be completed prior to implantation of the device.
  • Patient is a current alcohol or drug abuser
  • Patient is a prisoner
  • Patient known to be pregnant or breast feeding
  • Likely problems with maintaining follow-up program (e.g. patient with no fixed address, long distance, plans to move during course of study)
  • Not expected to survive the duration of the follow-up program
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    Treatment Group

    The population target is all subjects suffering clavicle fracture suitable for open reduction and internal fixation by the A.L.P.S. Clavicle Plating System in accordance with the IFU.

    Device: Clavicle open reduction and internal fixation

Interventions

  • DeviceClavicle open reduction and internal fixation

    Clavicle open reduction and internal fixation using the A.L.P.S. Clavicle Plating System

06

What researchers measure

Primary outcomes

  1. Number of subjects with fracture healing

    Number of subjects with fracture healing will be assessed through 12 months follow-up. Radiologic fracture healing is defined as: Bridging callus or no visible fracture lines on AP and 15-45° cephalic oblique radiographs.

    Time frame: 12 months

Secondary outcomes

  1. Frequency and Incidence of Adverse Events (Safety)

    Monitoring the frequency and incidence of adverse events, serious adverse events, adverse device effects, serious adverse device effects, and unanticipated serious adverse device effects as well as device deficiencies.

    Time frame: 12 months

  2. Range of Motion - Total shoulder motion

    Range of Motion (affected and contralateral), Forward elevation (maximum arm-trunk angle), External rotation (arm comfortably at side), External rotation (arm at 90 degrees of abduction), Internal rotation (thumb to back) spinous process, Cross-body adduction (antecubital fossa to opposite acromion (cm)

    Time frame: 12 months

  3. Clinical efficacy of the device is assessed using the American Shoulder and Elbow Surgeons (ASES) Shoulder Score at 12 months follow-up

    The ASES scale is 0-100. 100 is the highest score and indicates the greatest function while 0 is the lowest score.

    Time frame: 12 months

  4. Euroqol Patient Quality of life measured at 12 months follow-up (EQ-5D-5L)

    The EuroQol five dimensions questionnaire (EQ-5D-5L) is a five dimensional self-assessment that is comprised of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. These five dimensions can be used to index a subject's health utility on a scale of 0 to 1, where 0 is death and 1 is perfect health. The scoring rule for EQ-5D permits scores less than 0, implying that some health states may be worse than death.

    Time frame: 12 months

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2022 (actual). Primary completion is estimated for Dec 2026, 55 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2022
First posted
Apr 14, 2022
StartActual
May 13, 2022
Primary completionEst.
Dec 2026
CompletionEst.
Mar 2027
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05327959
Lead sponsor
Zimmer Biomet
Responsible party
Sponsor
First posted
Apr 14, 2022
Start date
May 13, 2022
Primary completion
Dec 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Feb 13, 2026

Study contacts

Hillary Overholser
study director · Zimmer Biomet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion